BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2025.
STRONG GROWTH AND CASH FLOW - CURRENCY SWINGS IMPACTING REPORTED EARNINGS
"Strong growth driven by solid market penetration." Emil Billbäck, CEO
JANUARY - MARCH 2025
- Net sales increased by 54 percent (50 percent at constant exchange rates) and amounted to SEK 283.5 million (184.4).
- The North America (NA) segment reported a sales growth of 63 percent (59 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 22 percent (21 percent at constant exchange rates).
- The gross margin amounted to 92.6 percent (92.6).
- The adjusted operating result amounted to SEK 39.7 million (41.6). The reported operating result amounted to SEK 29.6 million (32.3).
- Earnings per share before and after dilution were SEK 0.16 (0.33).
EVENTS DURING THE QUARTER
- As a result of the Swedish krona strengthening against both the USD, EUR and GBP in the quarter, with the greatest strengthening and effect related to the USD, operating profit was impacted with currency translation effects amounting to a negative SEK 30.4 million, of which SEK 27.6 million is unrealized.
- In January, a clinical study including 105 diabetes patients with bone infection in the foot, was reported, that showed that treatment with CERAMENT G or CERAMENT V gave significant advantages compared to standard treatment. The results showed improved infection healing and a dramatic improvement in survival rate to 87.5 percent compared to 44.9 percent in the standard treatment group, over a five-year period.
- At the end of March, the Company submitted market authorization application for its antibiotic eluting bone graft substitute, CERAMENT V in the US, with the Food and Drug Administration (FDA), for the indication bone infection.
EVENTS AFTER THE PERIOD
- The US Centers for Medicare & Medicaid Services (CMS) recommends NTAP of USD 5,688 for CERAMENT G and the indication open fractures. A final decision is expected in August 2025.
- CMS recommends a substantial increase in reimbursements for orthopedic procedures in extremities in inpatient care by 6 percent for 2026. A final decision is expected in August 2025.
For more information contact:
BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
Håkan Johansson, CFO
+46 (0) 46 286 53 70
ir@bonesupport.com
Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87
charlotte.stjerngren@cordcom.se
www.cordcom.se
This information is information that BONESUPPORT Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-04-24 08:00 CEST.
About BONESUPPORT
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 899 million in 2024. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.
